A new study published in the British Medical Journal suggests that Merck's cervical cancer vaccine, Gardasil, was more cost effective than the popularly used Cervarix manufactured by GlaxoSmithKline's (GSK).
The Department of Health in Britain had picked Cervarix as the cheaper option to be made available through NHS. According to the list price posted by NHS, Cervarix costs the service around £80.50 per dose compared to Gardasil's price tag of £88.50 per dose.
However the new study by Health Protection Agency (HPA) suggests that it is Gardasil that provides a more cost effective service compared to Cervarix.
The study said that while both the vaccines were effective against HPV types 16 and 18, Gardasil also provided protection against types 6 and 11. The researchers said that this made Gardasil a better prospect compared to Cervarix.